FDA Approval: SKYRIZI (RISANKIZUMAB-RZAA) — Type 1 - New Molecular Entity

Full alert analysis requires a subscription

Subscribe to access the complete alert summary, AI-generated action recommendations, source document links, LCD revision comparisons, and related alerts.